OpenResearchAlpha

Frontiers in Oncology · 13 Nov 2026

Adaptive immunotherapy dosing in cancer: a structured narrative review and conceptual framework for future clinical investigation

Nehemias Guevara Rodriguez, Abner A. Murray, Olayinka Fakorede, Mohamed M. Khamis, Noemy Coreas Mercado, Coral Olazagasti, Ranju Kunwor

0
Citations
no database records one yet
0
Citations in 2026
so far
–
Leading author's h-index
no author has a profile yet
100
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, but approved schedules do not establish whether treatment intensity should remain constant as tumor burden, immunity, toxicity, and response evolve. Continued treatment after durable response may add toxicity and treatment burden while providing uncertain incremental benefit. This structured narrative review examines adaptive immunotherapy dosing: prespecified, state-dependent modification of dose, interval, or duration, including interruption and resumption. Exposure–response plateaus and time-varying clearance support investigating alternative regimens but do not establish clinical equivalence. Evidence on discontinuation remains disease- and regimen-specific, precluding generalization from melanoma to non-small cell lung cancer or other settings. Response- and biomarker-guided strategies have prospective support in defined settings, including response-driven adjuvant therapy in melanoma and circulating tumor DNA–selected adjuvant therapy in muscle-invasive bladder cancer. These advances do not validate repeated biomarker-guided adjustment of ICI dose, interval, or duration. Most candidate longitudinal biomarkers show outcome associations without demonstrated utility for dosing adaptation. Artificial intelligence and computational models may integrate serial data but require prospective evaluation, external validation, and safeguards against unsafe individual predictions. Dynamic treatment regimes and adaptive trial methods offer tools for evaluating complete policies, with attention to endpoints, patient preferences, assay performance, equity, and regulation. The proposed conceptual framework organizes these requirements for prospective investigation; it is not a clinical algorithm. Trials must establish whether matching treatment intensity to an evolving clinical state preserves efficacy while reducing toxicity and burden and improving quality of life. Approved regimens and validated disease-specific strategies remain the clinical benchmark.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (7)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (100)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 80 more references

A free account opens the rest of the citing papers and references on every paper’s page.